Membership

Our members receive our quarterly e-newsletter with members-only content including interviews with dermatologists, information on contests and draws, and are the first to hear about upcoming events.

Membership is free.

Learn More

Etanercept (TNF Blocker)

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter

For psoriatic arthritis: 
50 mg once weekly

What Are The Possible Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®NoNohttps://pdf.hres.ca/dpd_pm/00060454.PDF27 Jun, 2024
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00069556.PDFFeb 09, 2023
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065129.PDF
AlbertaBiologics and BiosimilarsEtanerceptRymtiYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsetanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  https://pdf.hres.ca/dpd_pm/00060454.PDF
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069556.PDF
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065129.PDF
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.https://pdf.hres.ca/dpd_pm/00060454.PDF
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDShttps://pdf.hres.ca/dpd_pm/00069556.PDFDecember 8, 2015
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00065129.PDF
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®NoNohttps://pdf.hres.ca/dpd_pm/00060454.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00069556.PDF
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00065129.PDF
New BrunswickBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®NoNohttps://pdf.hres.ca/dpd_pm/00060454.PDF
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/Ahttps://pdf.hres.ca/dpd_pm/00069556.PDF
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/A Yes – S/A https://pdf.hres.ca/dpd_pm/00065129.PDF27 Jun, 2024
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- Only for clients who received approval for Enbrel before October 2, 2017https://pdf.hres.ca/dpd_pm/00060454.PDF
NIHBBiologics and BiosimilarsEtanerceptErelzi™NoYes- L/Uhttps://pdf.hres.ca/dpd_pm/00069556.PDF
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065129.PDF
NIHBBiologics and BiosimilarsEtanerceptRymtiNoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/Uhttps://pdf.hres.ca/dpd_pm/00060454.PDF
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00069556.PDF
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065129.PDF
Northwest TerritoriesBiologics and BiosimilarsEtanerceptRymtiNoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  https://pdf.hres.ca/dpd_pm/00060454.PDF
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDShttps://pdf.hres.ca/dpd_pm/00069556.PDF
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00065129.PDF
Nova ScotiaBiologics and BiosimilarsEtanerceptRymtiYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065129.PDF
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/Uhttps://pdf.hres.ca/dpd_pm/00060454.PDF
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00069556.PDF
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/Uhttps://pdf.hres.ca/dpd_pm/00065129.PDF
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes - EAPYes - EAPhttps://pdf.hres.ca/dpd_pm/00060454.PDF27 Jun, 2024
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/Uhttps://pdf.hres.ca/dpd_pm/00069556.PDF
OntarioBiologics and BiosimilarsEtanerceptRymtiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00060454.PDF
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069556.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065129.PDF27 Jun, 2024
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 https://pdf.hres.ca/dpd_pm/00060454.PDF
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A https://pdf.hres.ca/dpd_pm/00069556.PDF
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065129.PDF
QuebecBiologics and BiosimilarsEtanerceptRymtiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®NoNohttps://pdf.hres.ca/dpd_pm/00060454.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDShttps://pdf.hres.ca/dpd_pm/00069556.PDF
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00065129.PDF
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi https://pdf.hres.ca/dpd_pm/00060454.PDF
YukonBiologics and BiosimilarsEtanerceptErelzi™Yes - EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069556.PDF27 Jun, 2024
YukonBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00065129.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsEtanerceptRymtiNoYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068678.PDF27 Jun, 2024

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Brenzys®: https://pdf.hres.ca/dpd_pm/00065129.PDF
Enbrel®: https://pdf.hres.ca/dpd_pm/00060454.PDF
Erelzi™: https://pdf.hres.ca/dpd_pm/00069556.PDF
Rymti: https://pdf.hres.ca/dpd_pm/00068678.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi): Call 1-844-27XPOSE (1-844-279-7673) for information

Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf

Adalimumab (TNF Blocker)

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose

For psoriatic arthritis:
40 mg every other week

What Are The Possible Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsAdalimumabHumira®NoNohttps://pdf.hres.ca/dpd_pm/00067414.PDF 27 Jun, 2024
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDFDec 14, 2022
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDFDecember 22, 2022
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDFOctober 11, 2022
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDFOctober 30, 2020
AlbertaBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDFDec 9, 2022
AlbertaBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDFFebruary 3, 2023
AlbertaBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDFFebruary 14, 2022
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  https://pdf.hres.ca/dpd_pm/00067414.PDFJune 17, 2022
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDFApril 13, 2021
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDFJune 29, 2015
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDFDecember 13, 2021
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDFOctober 17, 2017
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDFAugust 10, 2018
British ColumbiaBiologics and BiosimilarsAdalimumabAbriladaYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsAdalimumabSimlandiYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsAdalimumabYuflymaYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.https://pdf.hres.ca/dpd_pm/00067414.PDF
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00068763.PDF
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00073497.PDF
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00058541.PDF
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00067468.PDF
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00071858.PDF
ManitobaBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
ManitobaBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
ManitobaBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsAdalimumabHumira®NoNohttps://pdf.hres.ca/dpd_pm/00067414.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDF
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDF
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDF
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDF
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDF
New BrunswickBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF
New BrunswickBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDF
New BrunswickBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.https://pdf.hres.ca/dpd_pm/00067414.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDF
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDF
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before June 11, 2021Yes- only for clients who received approval for Humira before June 11, 2021https://pdf.hres.ca/dpd_pm/00067414.PDF
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068763.PDF
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073497.PDF
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00058541.PDF
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067468.PDF
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00071858.PDF
NIHBBiologics and BiosimilarsAdalimumabAbriladaYes – L/UYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
NIHBBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075380.PDF
NIHBBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00069429.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067414.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068763.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073497.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00058541.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067468.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00071858.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
Northwest TerritoriesBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075380.PDF
Northwest TerritoriesBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00069429.PDF
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes- only for clients who received approval for Humira before December 15, 2021Yes- only for clients who received approval for Humira before December 15, 2021https://pdf.hres.ca/dpd_pm/00067414.PDF
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00068763.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00073497.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00058541.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00067468.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00071858.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067468.PDF
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068763.PDF
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00071858.PDF
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067414.PDF
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00058541.PDF
OntarioBiologics and BiosimilarsAdalimumabAbriladaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00067468.PDFMarch 13, 2015
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00068763.PDF
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00071858.PDF
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - EAPYes - EAPhttps://pdf.hres.ca/dpd_pm/00067414.PDF27 Jun, 2024
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073497.PDF
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00058541.PDF
OntarioBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075380.PDF
OntarioBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00069429.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067414.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDF
Prince Edward IslandBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.https://pdf.hres.ca/dpd_pm/00067414.PDF
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00068763.PDF
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073497.PDF
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00058541.PDF
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00067468.PDF
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00071858.PDF
QuebecBiologics and BiosimilarsAdalimumabAbriladaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00068228.PDF
QuebecBiologics and BiosimilarsAdalimumabSimlandiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075380.PDF
QuebecBiologics and BiosimilarsAdalimumabYuflymaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069429.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®NoNohttps://pdf.hres.ca/dpd_pm/00067414.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00068763.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00073497.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00058541.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00067468.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00071858.PDF
SaskatchewanBiologics and BiosimilarsAdalimumabAbriladaYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsAdalimumabSimlandiYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsAdalimumabYuflymaYes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00067414.PDF
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00068763.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00073497.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00058541.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00067468.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00071858.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabAbriladaYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00068228.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabSimlandiYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00075380.PDF27 Jun, 2024
YukonBiologics and BiosimilarsAdalimumabYuflymaYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00069429.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsAdalimumabSimlandiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075380.PDF
NunavutBiologics and BiosimilarsAdalimumabYuflymaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00069429.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Abrilada: https://pdf.hres.ca/dpd_pm/00068228.PDF
Amgevita®: https://pdf.hres.ca/dpd_pm/00067468.PDF
Hadlima®: https://pdf.hres.ca/dpd_pm/00068763.PDF
Hulio®: https://pdf.hres.ca/dpd_pm/00071858.PDF
Humira®: https://pdf.hres.ca/dpd_pm/00067414.PDF
Hyrimoz®: https://pdf.hres.ca/dpd_pm/00073497.PDF
Idacio®: https://pdf.hres.ca/dpd_pm/00058541.PDF
Simlandi: https://pdf.hres.ca/dpd_pm/00075380.PDF
Yuflyma: https://pdf.hres.ca/dpd_pm/00069429.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have. 

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

AbbVie Care Support Program
https://abbviecare.ca/

Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html

Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com

Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca

Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca

Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com

Infliximab (TNF Blocker)

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

What Are The Possible Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo https://pdf.hres.ca/dpd_pm/00075118.PDFJanuary 24, 2022
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065940.PDFJanuary 5, 2023
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDFFebruary 25, 2020
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®NoNo https://pdf.hres.ca/dpd_pm/00075118.PDF
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065940.PDF
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDF
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.https://pdf.hres.ca/dpd_pm/00075118.PDF
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00065940.PDF
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00057004.PDF
New BrunswickBiologics and BiosimilarsInfliximabRemicade®NoNohttps://pdf.hres.ca/dpd_pm/00075118.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00065940.PDF
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). Nohttps://pdf.hres.ca/dpd_pm/00075118.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SAhttps://pdf.hres.ca/dpd_pm/00065940.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDF
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNohttps://pdf.hres.ca/dpd_pm/00075118.PDF
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065940.PDF
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00057004.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNohttps://pdf.hres.ca/dpd_pm/00075118.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065940.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00057004.PDF
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. https://pdf.hres.ca/dpd_pm/00075118.PDF
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00065940.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00057004.PDF
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00065940.PDF
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00057004.PDF
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNohttps://pdf.hres.ca/dpd_pm/00075118.PDF
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00072737.PDF
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00065940.PDF
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00057004.PDF
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075118.PDF
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00065940.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDF
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 https://pdf.hres.ca/dpd_pm/00075118.PDF
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00065940.PDF
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00057004.PDF
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®NoNohttps://pdf.hres.ca/dpd_pm/00075118.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00065940.PDF
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00057004.PDF
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.https://pdf.hres.ca/dpd_pm/00075118.PDF
YukonBiologics and BiosimilarsInfliximabAvsola®NoNohttps://pdf.hres.ca/dpd_pm/00065940.PDF
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00057004.PDF
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDFNov 14, 2022
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00072737.PDF
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
NIHBBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
NIHBBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00072737.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00072737.PDF
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00072737.PDF
OntarioBiologics and BiosimilarsInfliximabRemicade®Yes - EAPYes - EAPhttps://pdf.hres.ca/dpd_pm/00075118.PDF
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00072737.PDF
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00072737.PDF
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00072737.PDF
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNohttps://pdf.hres.ca/dpd_pm/00068865.PDF
YukonBiologics and BiosimilarsInfliximabRemsima™NoNohttps://pdf.hres.ca/dpd_pm/00074581.PDF
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00072737.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Avsola®: https://pdf.hres.ca/dpd_pm/00065940.PDF
Inflectra®: https://pdf.hres.ca/dpd_pm/00057004.PDF
Omvyence™: https://pdf.hres.ca/dpd_pm/00068865.PDF
Remicade®: https://pdf.hres.ca/dpd_pm/00075118.PDF
Remsima™: https://pdf.hres.ca/dpd_pm/00074581.PDF
Renflexis®: https://pdf.hres.ca/dpd_pm/00072737.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: http://www.merckharmony.ca/

Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.cawww.avsola.ca

Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/

Certolizumab pegol (TNF Blocker)

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
400 mg every 2 weeks

For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

What Are The Possible Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of  upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDFJan 18, 2023
British ColumbiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes - S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDFAug 02, 2022
ManitobaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00053920.PDF
New BrunswickBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDF
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDFSeptember 12, 2019
NIHBBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/Uhttps://pdf.hres.ca/dpd_pm/00053920.PDF
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/Uhttps://pdf.hres.ca/dpd_pm/00053920.PDF
Nova ScotiaBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00053920.PDF
NunavutBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – L/Uhttps://pdf.hres.ca/dpd_pm/00053920.PDF
OntarioBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EAPhttps://pdf.hres.ca/dpd_pm/00053920.PDF
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDF
QuebecBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00053920.PDF
SaskatchewanBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00053920.PDF
YukonBiologics and BiosimilarsCertolizumab pegolCimzia®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00053920.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00053920.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCB Cares 1-800-908-5555

Golimumab (TNF Blocker)

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDShttps://pdf.hres.ca/dpd_pm/00074084.PDF
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/Uhttps://pdf.hres.ca/dpd_pm/00074084.PDF
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/Uhttps://pdf.hres.ca/dpd_pm/00074084.PDF
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00074084.PDF
OntarioBiologics and BiosimilarsGolimumabSimponi®N/AYes - EAPhttps://pdf.hres.ca/dpd_pm/00074084.PDF
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00074084.PDF
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDShttps://pdf.hres.ca/dpd_pm/00074084.PDF
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDShttps://pdf.hres.ca/dpd_pm/00074084.PDF
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/Uhttps://pdf.hres.ca/dpd_pm/00074084.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00074084.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Ixekizumab (IL17 Blocker)

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks

For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks

What Are The Possible Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069828.PDF
ManitobaBiologics and BiosimilarsIxekizumabSiliq™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00069828.PDF
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00069828.PDF
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069828.PDF
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes - EAPhttps://pdf.hres.ca/dpd_pm/00069828.PDF
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00069828.PDF
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00069828.PDF
YukonBiologics and BiosimilarsIxekizumabTaltz®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00069828.PDF
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00069828.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00069828.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

 

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-877-219-8908 for information.

Brodalumab (IL17 Blocker)

How Does It Work?

Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.

How Is It Used?

Brodalumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks

What Are The Possible Side Effects?

The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.

Brodalumab should be avoided in patients with Crohn’s disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDFMarch 17, 2022
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNohttps://pdf.hres.ca/dpd_pm/00075300.PDF
YukonBiologics and BiosimilarsBrodalumabSiliq™NoN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075300.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075300.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-844-852-6967 for information.

Secukinumab (IL17 Blocker)

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks

For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

What Are The Possible Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00075631.PDF
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075631.PDF
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00075631.PDF
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00075631.PDF
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00075631.PDF
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes - EAPhttps://pdf.hres.ca/dpd_pm/00075631.PDF
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075631.PDF
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075631.PDF
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075631.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075631.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have. 

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Bimekizumab (IL17 Blocker)

How Does It Work?

Bimekizumab works by inhibiting the inflammatory proteins known as IL-17A and IL-17F. These inflammatory proteins are present in increased levels in psoriasis and by inhibiting them, this medication can help to achieve skin clearance and improvement in psoriasis symptoms.

How Is It Used?

Bimekizumab is an injectable medication that is administered subcutaneously. Patients can self-inject at home.

Bimekizumab is approved for the treatment of psoriasis. The recommended dose is 320mg (given as 2 subcutaneous injections of 160mg each) every 4 weeks for the first 16 weeks and then every 8 weeks thereafter.
If you weigh more than 120 kg, your healthcare professional may decide to continue your injections every 4 weeks from week 16. Follow your doctor’s instructions for optimal dosing.

Bimekizumab is available as a pre-filled syringe or autoinjector.

What Are The Possible Side Effects?

The most common side effects of bimekizumab include an increased risk of upper respiratory tract infection. To obtain a comprehensive list of all known potential side effects of bimekizumab, talk to your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on bimekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is safe to receive while on bimekizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Bimekizumab is not recommended in patients with inflammatory bowel disease.

What Medications Interact With This Treatment?

For a complete list of medications that may interact with bimekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsBimekizumabBimzelxYes - S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
ManitobaBiologics and BiosimilarsBimekizumabBimzelxYes - EDSNohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
NIHBBiologics and BiosimilarsBimekizumabBimzelxNoNohttps://pdf.hres.ca/dpd_pm/00074908.PDF
Northwest TerritoriesBiologics and BiosimilarsBimekizumabBimzelxNoNohttps://pdf.hres.ca/dpd_pm/00074908.PDF
Nova ScotiaBiologics and BiosimilarsBimekizumabBimzelxYes – EDSNohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsBimekizumabBimzelxNoNohttps://pdf.hres.ca/dpd_pm/00074908.PDF
OntarioBiologics and BiosimilarsBimekizumabBimzelxYes - L/UNohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
QuebecBiologics and BiosimilarsBimekizumabBimzelxYes – S/ANohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsBimekizumabBimzelxYes - EDSNohttps://pdf.hres.ca/dpd_pm/00074908.PDF27 Jun, 2024
YukonBiologics and BiosimilarsBimekizumabBimzelxNoNohttps://pdf.hres.ca/dpd_pm/00074908.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00074908.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCBCares Patient Support Program
1-800-908-5555
www.UCBCares.ca

Ustekinumab (IL12/23 Blocker)

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANohttps://pdf.hres.ca/dpd_pm/00073994.PDF
AlbertaBiologics and BiosimilarsUstekinumabWezlanaYes – S/ANohttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
AlbertaBiologics and BiosimilarsUstekinumabJamtekiYes – S/ANohttps://pdf.hres.ca/dpd_pm/00073286.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/A until Dec 3 2024Nohttps://pdf.hres.ca/dpd_pm/00073994.PDF
British ColumbiaBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073286.PDF27 Jun, 2024
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
New BrunswickBiologics and BiosimilarsUstekinumabStelara®NoNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
New BrunswickBiologics and BiosimilarsUstekinumabJamtekiYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073286.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsUstekinumabWezlanaYes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANohttps://pdf.hres.ca/dpd_pm/00073994.PDF
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073286.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
NIHBBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
Northwest TerritoriesBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDSNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
Nova ScotiaBiologics and BiosimilarsUstekinumabJamtekiYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00073286.PDF
Nova ScotiaBiologics and BiosimilarsUstekinumabWezlanaYes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
NunavutBiologics and BiosimilarsUstekinumabWezlanaYes – L/UYes – L/Uhttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNohttps://pdf.hres.ca/dpd_pm/00073994.PDF
OntarioBiologics and BiosimilarsUstekinumabJamtekiYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073286.PDF
OntarioBiologics and BiosimilarsUstekinumabWezlanaYes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANohttps://pdf.hres.ca/dpd_pm/00073994.PDF
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073994.PDF
QuebecBiologics and BiosimilarsUstekinumabJamtekiYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073286.PDF
QuebecBiologics and BiosimilarsUstekinumabWezlanaYes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00073953.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00073994.PDF
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNohttps://pdf.hres.ca/dpd_pm/00073994.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Jamteki: https://pdf.hres.ca/dpd_pm/00073286.PDF
Stelara®: https://pdf.hres.ca/dpd_pm/00073994.PDF
Wezlana: https://pdf.hres.ca/dpd_pm/00073953.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Risankizumab (IL23 Blocker)

How Does It Work?

Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.

How Is It Used?

The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. 

What Are The Possible Side Effects?

The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

N/A

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A N/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00075159.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075159.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Guselkumab (IL23 Blocker)

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.

 

What Medications Interact With This Treatment?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

 

 

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsGuselkumabTremfya®Yes - S/AYes - S/Ahttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNohttps://pdf.hres.ca/dpd_pm/00075605.PDF
ManitobaBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®Yes – S/A Yes – S/A https://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
NIHBBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®Yes – EDSYes – EDShttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
OntarioBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - EAPhttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®Yes – S/AYes – S/Ahttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
QuebecBiologics and BiosimilarsGuselkumabTremfya®Yes - S/ANohttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®Yes - EDSYes - EDShttps://pdf.hres.ca/dpd_pm/00075605.PDF27 Jun, 2024
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNohttps://pdf.hres.ca/dpd_pm/00075605.PDF
NunavutBiologics and BiosimilarsGuselkumabTremfya®Yes - L/UYes - L/Uhttps://pdf.hres.ca/dpd_pm/00075605.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075605.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDFJuly 21, 2022
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDFApril 4, 2016
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. https://pdf.hres.ca/dpd_pm/00070861.PDF
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF
YukonBiologics and BiosimilarsAbataceptOrencia®NoNohttps://pdf.hres.ca/dpd_pm/00070861.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00070861.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Tildrakizumab

How Does It Work?

Ilumya™ acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.

How Is It Used?

Ilumya™ is a drug taken by injection often in 12-week intervals.

What Are The Possible Side Effects?

Side effects of Ilumya™ can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.

Any Other Important Considerations?

Not applicable

What Medications Interact With This Treatment?

Certain vaccines cannot be taken while on Ilumya™. Talk to your doctor before being vaccinated to confirm it is safe to do so while on Ilumya. Ilumya may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:
NunavutBiologics and BiosimilarsTildrakizumabIlumya™NoN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
NIHBBiologics and BiosimilarsTildrakizumabIlumya™Yes – L/UN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™NoN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™Yes – EDSN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
OntarioBiologics and BiosimilarsTildrakizumabIlumya™Yes - L/UN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™Yes – S/AN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF27 Jun, 2024
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDSN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF
YukonBiologics and BiosimilarsTildrakizumabIlumya™NoN/Ahttps://pdf.hres.ca/dpd_pm/00064464.PDF

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00064464.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

SPEVIGO® (IL 36 Blocker)

How Does It Work?

SPEVIGO (spesolimab for injection) inhibits the inflammatory signaling pathway of interleukin 36 (IL-36), and is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).

How Is It Used?

Treatment with SPEVIGO (spesolimab for injection) should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.

The recommended dose of SPEVIGO (spesolimab for injection) is a single dose of 900 mg (2 x 450 mg/7.5 ml vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.

What Are The Possible Side Effects?

The most common side effects of SPEVIGO (spesolimab for injection) include fatigue/weakness, nausea and vomiting, headache, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, and urinary tract infection. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.

Any Other Important Considerations?

SPEVIGO (spesolimab for injection) is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredients in the formulation, including any non-medicinal ingredients, or components of the container.

What Medications Interact With This Treatment?

No formal drug-drug interaction studies were conducted with SPEVIGO (spesolimab for injection). For a complete list of medications that may interact with SPEVIGO (spesolimab for injection) and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic ArthritisMonographDate of Revision:

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102523

https://pdf.hres.ca/dpd_pm/00070263.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

headstartGO@supportprogram.com

Call toll-free: 1-833-773-4746

MedInfo can be accessed by health care providers for possible inquiries (1-800-263-5103 x84643, zrburmedinfo@boehringer-ingelheim.com).

Last updated May 31, 2024.